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O B J E C T I V E S We evaluated whether myeloperoxidase (MPO) predicts future cardiovascular disease
(CVD) events in asymptomatic adults and whether subclinical atherosclerosis may affect this relation.
B A C KG ROUND Myeloperoxidase is a leukocyte-derived enzyme-generating reactive oxidant
species that has been shown to predict risk of CVD in selected populations.
METHOD S We studied 1,302 asymptomatic adults (mean age 59 years, 47% women) without
known CVD who were followed for 3.8 years. We measured MPO by the use of immunoassay. Coronary
artery calcium (CAC), a measure of subclinical atherosclerosis, was measured by computed tomography
with the Agatston score categorized as none/minimal (0 to 9), mild (10 to 99), and moderate/signiﬁcant
(100). Cox regression, adjusted for age, sex, and other risk factors, examined the relation of CAC and/or
MPO with incident CVD events.
R E S U L T S Persons with MPO levels at or above compared with below the median (257 pM) were
more likely (p  0.05 to p  0.001) to be women, have a higher body mass index, greater low-density
lipoprotein cholesterol, greater systolic and diastolic blood pressure, and lower high-density lipoprotein
cholesterol. Mean MPO levels increased according to CAC categories (p trend  0.02). Incident CVD
events were more likely in those at or above versus below the median MPO level (4.6% vs. 2.3%, p 
0.02), even after adjustment for age, sex, CAC, and risk factors (hazard ratio [HR]: 1.9, 95% conﬁdence
interval: 1.0 to 3.6, p  0.04). Combining CAC and MPO categories, CVD incidence ranged from 0.6% in
those with a CAC score of 0 to 9 to 7.1% (adjusted HR: 9.2, p  0.001) in those with CAC scores of 100
and MPO below the median and 14.0% (adjusted HR: 19.5, p 0.0001) in those with CAC scores of100
and MPO at or above the median.
CONC L U S I O N S Our study suggests persons with both increased levels of both MPO and CAC are
at an increased risk of CVD events. Imaging of subclinical atherosclerosis combined with assessment of
biomarkers of plaque vulnerability may help improve CVD risk stratiﬁcation. (J Am Coll Cardiol Img
2009;2:1093–9) © 2009 by the American College of Cardiology Foundation
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1094yeloperoxidase (MPO) is a leukocyte-
derived enzyme-generating reactive oxi-
dant species that may be atherogenic (1).
Potential mechanisms that may relate to
PO promoting vascular disease include the follow-
ng: stimulating conversion of low-density lipoprotein
LDL) into an atherogenic form, selectively modify-
ng apolipoprotein A-1 and generating dysfunctional
igh-density lipoprotein (HDL), promoting endothe-
ial dysfunction, promoting vulnerable plaque, and
romoting myocardial dysfunction and abnormal ven-
ricular remodeling after myocardial infarction (MI).
See page 1100
In 1,090 patients with acute coronary syndrome,
hose with increased levels of MPO (350 g/l;
1.3%) had an increased cardiac risk (adjusted hazard
atio [HR]: 2.25 [95% confidence interval (CI): 1.32
to 3.82], p  0.003) (2). In 512 patients
with acute MI, levels of MPO above the
median predicted mortality (odds ratio: 1.8,
95% CI: 1.0 to 3.0, p  0.034) (3). Also,
levels of MPO were associated with the
future risk of coronary artery disease in
apparently healthy individuals in the Euro-
pean Prospective Investigation into Cancer-
Norfolk Prospective Population Study, a
nested case-control study (1,138 cases and
2,237 control patients) with 8-year follow-
up, with an adjusted odds ratio for the
highest quartile of MPO 1.36, 95% CI: 1.07
to 1.73 (4). Coronary artery calcium (CAC)
is a well-established measure of subclinical
atherosclerosis, and the authors of numerous
ohort studies (5) show its strong relation to future
ardiovascular events and mortality in asymptomatic
ndividuals.
However, the association of MPO with subclin-
cal atherosclerosis is not established. In addition,
here are limited data on the combined utility of
maging of subclinical atherosclerosis and assess-
ent of biomarkers, such as MPO, for identifying
atients at increased risk of cardiovascular events.
e evaluated whether MPO predicts future cardio-
ascular disease (CVD) events in asymptomatic
dults and specifically whether this may depend on
he extent of atherosclerotic burden present.
E T H O D S
e studied 1,302 adults (mean age 59 years, 47%
m
e
teinomen) without known cardiovascular disease or ymptoms, within the EISNER (Early Identification
f Subclinical Atherosclerosis by Noninvasive Imag-
ng Research) research study. The current study was
pproved by the Cedars-Sinai Medical Center Insti-
utional Review Board (institutional research board
umbers 3351, 3354, and 3974). Follow-up for inci-
ent CVD events (MI, revascularization, stroke, or
VD death) was available for an average of 3.8 years.
ardiovascular events were reviewed and adjudicated
y study physicians. Standardized assessment of car-
iovascular risk factors was available among partici-
ants. Serum and ethylene diamine tetraacetic acid
lasma samples were stored at70°C for up to 4 years
ntil all baseline samples were accumulated.
We measured MPO using an immunoassay (Bio-
ite, an Inverness Medical Company, Waltham, Mas-
achusetts). The ethylene diamine tetraacetic acid
lasma sample, once treated with reagents on the test
evice, reacts with florescent antibody conjugates,
roviding fluorescent signals from which the marker
oncentrations are calculated on the basis of reference
lasma samples. A moderately high correlation of 0.79
ith a near 1:1 correspondence (slope  1.07) was
bserved between measurements of the Biosite assay
ompared with that of the Prognostix CardioMPO
ssay (protocol CLN0002, Biosite, Inc., personal
ommunication) over a wide range of measurements
xtending to 5,000 pM. A coefficient of variability of
2% has been reported at a mean level of 306 pM (lot
33318, Biosite, Inc.) (William Arnold, PhD, per-
onal communication, April 2009).
Subjects were scanned by the use of either electron
eam computed tomography (General Electric/
matron, South San Francisco, California) or by a
ultidetector scanner (Siemens, Munich, Germany).
he imaging protocol involved an experienced li-
ensed radiologic technician acquiring a single scan on
ach patient consisting of approximately 30 to 40
-mm slices encompassing the heart from the carina
o the apex, performed at 50% electrocardiographic
riggering in an attempt to minimize motion artifact.
nstructions on breath-holding also were given to
inimize misregistration. Foci of CAC were identi-
ed and scored by an experienced technician, who
sed semiautomatic commercial software (ScImage,
nc., Los Altos, California), and the scoring was
erified by an imaging cardiologist.
The software initially calculated lesion-specific
cores as the product of the area of each calcified
ocus and peak computed tomography number
scored as 1 if 130 to 199 Hounsfield Units [HU],
if 200 to 299 HU, 3 if 300 to 399 HU, and 4 ifB B R E V I A T I O N S
N D A C R O N YM S
UC area under the curve
AC coronary artery calciu
I confidence interval
VD cardiovascular diseas
DL-C high-density
ipoprotein cholesterol
R hazard ratio
DL-C low-density lipopro
holesterol
Imyocardial infarction400 HU). These were summed across all lesions
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1095dentified within left main, left anterior descending,
eft circumflex, and right coronary arteries to pro-
ide arterial specific calcium scores and across ar-
eries to provide a total Agatston calcium score used
or analysis (6). The quantity of CAC was catego-
ized as none/minimal (0 to 9), mild (10 to 99),
oderate (100 to 399), or significant (400).
A fasting lipid profile (total and HDL cholesterol
HDL-C], triglycerides, with calculated LDL cho-
esterol [LDL-C] based on the Friedwald equation)
lus glucose was performed on each study partici-
ant by a point-of-care analyzer (Cholestech, an
nverness Medical Company). Two readings of
lood pressure (with mean systolic and diastolic
eadings used for analysis) and weight and height
or calculation of body mass index also were ob-
ained. A brief medical history to assess previous
istory of cardiac disease, diabetes, and medication
sage also was taken. Diabetes was defined as a
elf-reported history of being told by a physician that
iabetes was present, taking diabetes medications, or
aving a fasting glucose of 7.0 mmol/l (126 mg/dl) or
reater or a casual glucose of 11.1 mmol/l (200 mg/dl)
r greater. A 10-year risk of coronary heart disease was
stimated by the Framingham risk score algorithms of
he National Cholesterol Education Program (7).
hose with diabetes were defined as coronary heart
isease risk equivalents and assigned a risk score of
0% (or greater if determined as such by the Fram-
ngham risk score calculation).
Follow-up for CVD events consisted of adminis-
ering patient questionnaires, patient interviews,
nd/or using hospital records to obtain outcome data
n consented patients. The incidence of MIs, strokes,
nd deaths were verified by 2 physicians from inde-
endent review of admission reports, discharge sum-
aries, and consultation/lab reports. Revasculariza-
ions were verified by hospital records. All deaths were
erified by National Death Index and/or independent
eview of death reports by 2 physicians. For analytic
urposes, total CVD events included MI or cardiac
eath, late revascularizations (90 days), and stroke.
Continuous variables were assessed between 2
roups by the use of the Student t test, whereas
ategorical variables were assessed by use of the
earson chi-square test or Fisher exact test for cell
ounts of6. Cuzick’s nonparametric test for trend
or continuous variables (e.g., mean MPO by CAC
ategory) and the log-rank test of trend for com-
arison of CVD event rates across MPO and/or
AC categories were applied. The Student t test or
hi-square test of proportions was used initially to
xamine the relationships of risk factors betweenhose with MPO levels at or above versus below the
edian. Also, we used multiple logistic regression
o examine for risk factors independently associated
ith increased MPO levels. Cox regression, ad-
usted for age, sex, and other risk factors (LDL-C,
DL-C, systolic blood pressure, diabetes, and cur-
ent smoking), was used to examine the relationship
f MPO and CAC to CVD events. Analyses were
erformed with MPO examined above versus below
he median and also continuously by natural log
ransformation. Finally, from the Cox model-
redicted relative hazards, we examined using
eceiver-operator characteristic analyses, whether
PO and/or CAC provided incremental value to
rediction of CVD events over models with stan-
ard risk factors alone. Curves were compared with
he method of DeLong et al. (8).
E S U L T S
able 1 displays the clinical characteristics of age,
ex, risk factors, by MPO level at or above the
edian (257 pM) versus below the median level.
atients with greater MPO levels were significantly
ore likely to be women, have greater body mass
ndex, greater LDL-C, lower HDL-C, and to have
reater systolic and diastolic blood pressure. There
as a trend (p  0.15) for greater CAC levels in
hose with higher versus lower MPO levels. More-
ver, Figure 1 shows mean MPO levels to be
reater according to increasing CAC categories
Table 1. Study Sample Characteristics by MPO Category
Variable
MPO Below Median
(<257 pmol/l)
n  649
MPO At or Abo
(>257 pm
n  6
Age (yrs) 58.3 8.2 58.8
Sex (% female) 43.8 49.8
Body mass index (kg/m2) 26.6 4.7 28.6
Diabetes (%) 7.7 8.3
Current smoking (%) 6.9 6.6
LDL-C (mg/dl) 132.4 37.8 138.7
HDL-C (mg/dl) 55.4 16.7 52.5
Systolic BP (mm Hg) 131.7 17.5 134.8
Diastolic BP (mm Hg) 81.4 10.7 82.9
Framingham risk (%) 8.3 6.9 9.0
CAC scores (%)
0–9 58.7* 53.5
10–99 19.6 23.6
100–399 14.2 13.6
400 7.6 9.3
*p  0.15 comparing distribution of MPO levels across CAC categories.
BP  blood pressure; CAC  coronary artery calcium; HDL-C  high-densitve Median
ol/l)
53
p
Value
8.7 0.36
0.03
5.7 0.0001
0.71
0.80
40.5 0.004
16.1 0.001
17.6 0.001
11.0 0.02
7.3 0.08
y lipoprotein cholesterol;
LDL-C  low-density lipoprotein cholesterol; MPO  myeloperoxidase.
(
o
I
s
o
i
H
m
(
M
q
i
a
2
(
C
s
H
s
v
o
p
w
l
n
a
e
t
a
l
r
(
r
e
l
e
r
(
i
1

i
M
C
f
w
gories. CAC  coronar
median. CVD  cardio
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 9 , 2 0 0 9
S E P T E M B E R 2 0 0 9 : 1 0 9 3 – 9
Wong et al.
Myeloperoxidase and Coronary Heart Disease
1096p trend  0.02), although after adjustment for
ther risk factors this relationship was attenuated.
n a separate multiple logistic regression (results not
hown), factors independently associated with the
dds of having greater MPO levels were body mass
ndex (p  0.001) and LDL-C (p  0.001), with
DL-C being inversely associated (p  0.001) and
ale sex being associated with a lesser likelihood
CAC Category
0-9 10 to 99 100-399 400+
294
308
327
318
of Myeloperoxidase Level (pM) by CAC Category
eroxidase are shown according to CAC category (0 to 9, 10 to 99,
. Cuzick’s nonparametric test of trend p  0.02 across CAC cate-
y artery calcium.
MPO Quartile
2.2%
2.5%
4.3%
1st 2nd 3rd 4th
4.9%
PO and CVD Event Risk (%)
tage of subjects with CVD events is shown according to MPO
of trend p  0.04 across MPO quartiles; p  0.02 comparing
fourth quartiles) versus below (ﬁrst and second quartiles)C
vascular disease; MPO  myeloperoxidase.odds ratio: 0.54, p  0.001) of having greater
PO levels.
Figure 2 shows CVD event risk to increase by
uartile of MPO level (trend p 0.05). The overall
ncidence of CVD events was 3.5%. Persons at or
bove versus below the median MPO level had a
-fold greater CVD event rate at 4.6% versus 2.3%
p  0.02 or 1.2%/year vs. 0.6%/year, p  0.02). In
ox proportional hazards regression (results not
hown), adjusted for age, sex, LDL-C and
DL-C, systolic blood pressure, diabetes, and
moking, increased MPO (at or above the median
s. below) levels remained independently predictive
f CVD events (HR: 2.0, 95% CI: 1.05 to 3.74,
 0.034). This relationship was slightly weaker
hen MPO was examined continuously (natural
og-transformed): HR: 1.7; CI: 0.98 to 3.1 per
atural log unit, p  0.06.
Table 2 shows the incidence of CVD events and
ge, sex, and risk factor-adjusted HRs for CVD
vents according to CAC and MPO categories
ogether. Although CAC was the main factor
ssociated with increased CVD event rates, MPO
evels at or above versus below the median level
emained an independent predictor of CVD events
HR: 1.9, p  0.04).
In a similar model with CAC and MPO catego-
ies combined (Table 3), in those with both mod-
rate and significant CAC (scores100) and MPO
evels at or above the median, the risk of CVD
vents was increased. The incidence of CVD
anged from 0.6% in those with CAC 0 to 9
regardless of MPO) to 7.1% (HR: 9.2, p  0.001)
n those with CAC 100 and lower MPO and
4.0% (HR: 19.5, p  0.0001) in those with CAC
100 and higher MPO. Event risk is also displayed
n Figure 3.
Finally, when we examined the overall utility of
PO and/or CAC to improve the prediction of
VD events, compared with age, sex, and risk
actors alone where the area under the curve (AUC)
as 0.755, significant improvement in prediction of
Table 2. Multivariable Cox Proportional Hazards Regression
for Cardiovascular Disease Events
Adjusted HR (95% CI) p Value
CAC 10–99 vs. 0–9 4.6 (1.4–15.1) 0.01
CAC 100 vs. 0–9 14.2 (4.7–42.6) 0.001
MPO 257 pM (median) 1.9 (1.0–3.6) 0.04
Estimates adjusted for age, sex, LDL-C, HDL-C, diabetes, smoking, and systolic
blood pressure.
CI  conﬁdence interval; HR  hazard ratio; other abbreviations as in Table 1.270
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1097ontaining combined MPO-CAC categories (AUC 
.838, p  0.0037) and CAC categories alone
AUC  0.833, p  0.005) but not MPO alone
AUC  0.762, p  0.59). Moreover, there was no
mprovement from adding MPO to a model with
ge, sex, risk factors, and CAC (AUC  0.838 vs.
.833, p  0.53).
I S C U S S I O N
e show in this report levels of MPO to be modestly
ssociated with the degree of subclinical atherosclero-
is burden noted by increased levels of CAC. Further,
e confirm other reports of a modest increase in
ardiovascular event risk associated with greater MPO
evels among those with acute coronary syndrome (2),
yocardial infarction (3), and those asymptomatic
ithout known coronary disease (4), which remained
ignificant even after adjusting for other risk factors.
f note, among persons with at least a moderate
egree of subclinical atherosclerosis (CAC scores
100) who also had increased levels of MPO, CVD
vent risk was increased.
Numerous prospective studies (2,3,9–12) among
ersons with stable or unstable coronary artery disease
ave shown an association between elevated MPO
evels and future CVD event risk. The EPIC-Norfolk
tudy is the only other epidemiologic study of initially
ealthy individuals to examine the relationship of
PO with future event risk and found a 1.5-fold
ncreased risk of coronary heart disease events among
ersons in the highest quartile of MPO levels, even
fter adjusting for standard risk factors (4). We note
he risk of CVD events to be increased once MPO
evels are above the median (approximately 257 pm) in
ur population, a finding that persists after adjustment
or other risk factors.
This is the first report examining the relation of
PO with CAC as a measure of subclinical ath-
rosclerosis. We find a significant (p  0.02) trend
f increasing mean MPO levels according to in-
reased levels of CAC, although this relationship
as attenuated after adjustment for other risk fac-
ors. Others have previously reported MPO levels
o independently predict other measures of subclin-
cal atherosclerosis such as endothelial dysfunction
13) and carotid stenosis in persons with low
DL-C (14) but not carotid atherosclerosis in
ersons with familial hypercholesterolemia (15).
Our study showed that the extent of subclinical
therosclerosis may help identify where biomarkers
uch as MPO may be most useful for identifying
ersons at greater risk. Although this relationship hasot been examined with other subclinical atheroscle-
osis measures, other studies have examined the prog-
ostic importance of MPO combined with other
iomarkers. The EPIC-Norfolk study showed per-
ons with MPO levels above the median who also had
-reactive protein levels2 mg/l were at a significant
.4-fold greater risk of coronary heart disease events,
reater than what increased levels of MPO conferred
lone (1.5-fold greater risk) (4).
In addition, Khan et al. (12) showed the combi-
ation of MPO and N-terminal pro-B-type natri-
retic peptide levels to improve prognostication
n high-risk patients. We also demonstrate from
eceiver-operating characteristics analyses that al-
hough combined MPO-CAC groups significantly
mproved prediction of CVD events over age, sex,
nd risk factors alone, this finding was explained
xclusively by CAC. The level of MPO alone did
ot add incremental value to prediction over age,
ex, and risk factors with or without CAC. Our data
0.0
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4.0
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Figure 3. Event Risk of CVD (%) by Combined MPO and CAC Gr
The cumulative proportion of subjects with CVD events is shown ac
bined MPO and CAC group; log-rank test for trend p  0.001. Abbr
Table 3. Multivariable Cox Proportional Hazards Regression of
MPO Categories
CAC Score
MPO Level,
pM
Incidence of CVD
Events, n (%)
Adjust
(95%
0–9 4/730 (0.55) 1.0 (ref
10–99 257 4/127 (3.2) 4.4 (1.1
10–99 257 6/154 (3.9) 5.2 (1.4
100 257 10/141 (7.1) 9.2 (2.7
100 257 21/150 (14.0) 19.5 (6.3
Estimates adjusted for age, sex, LDL-C, HDL-C, diabetes, smoking, and systo
Reliability of the estimates may be affected by the small number of events in
Abbreviations as in Table 2.14.0%
7 pm
oup
cording to com-
eviations as inCombined CAC and
ed HR
CI) p Value
erence)
–18.0) 0.039
–18.8) 0.012
–31.0) 0.001
–60.0) 0.001
lic blood pressure. Note:
the reference group.Figures 1 and 2.
s
i
S
c
t
i
e
o
v
m
a
s
a
c
o
i
e
a
w
o
p
b
m
s
p
a
i
u
r
t
C
O
i
r
i
t
a
b
d
p
w
a
o
v
p
A
T
t
p
R
m
C
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 9 , 2 0 0 9
S E P T E M B E R 2 0 0 9 : 1 0 9 3 – 9
Wong et al.
Myeloperoxidase and Coronary Heart Disease
1098howing CAC to add to prediction over risk factors
s consistent with other previous reports (16–18).
tudy limitations. Our primary end point was a
omposite of CVD events, including revasculariza-
ions; we did not have an adequate number of
ndividual hard end points (e.g., MIs or strokes) to
xamine these end points separately. In addition,
ur results apply principally to asymptomatic indi-
iduals who comprised our population; findings
ay differ for other higher-risk populations (e.g.,
cute coronary syndromes) where MPO has been
hown to be an even stronger risk factor. Also,
lthough our Cox model could be overfitted with 7
ovariates, we are able to demonstrate stability in
ur key estimates based on a simpler model adjust-
ng for Framingham risk score only, which results in
ssentially unchanged estimates for combined CAC
nd MPO categories. Finally, our study population
as composed primarily of Caucasian patients, so
ur findings cannot be generalized to more diverse
opulations.
Our study demonstrates the potential utility of a
iomarker such as MPO in combination with imaging
easures to help identify higher-risk persons. Further
tudies are needed to examine which biomarkers
erform best with which specific imaging modalities
nd in which patient subgroups (e.g., asymptomatic,
ntermediate risk, stable coronary disease, youngerassessment and in evaluation of patients
Pearson DL. Com
under two or moresed for this purpose should be low cost, free of
adiation, and easily measured at the time of imaging
o provide sustained utility in the clinical setting.
O N C L U S I O N S
ur report suggests that persons who have both
ncreased levels of MPO and CAC have an increased
isk of CVD events. Although greater CAC scores
mply there is generally more extensive disease and
hus a greater likelihood of vulnerable plaques, adding
marker such as MPO helps refine this relationship
y further identifying those with active versus stable
isease. Therefore, MPO may serve as a marker of
laque vulnerability, which is more common in those
ith greater CAC scores. Imaging of subclinical
therosclerosis combined with biomarker assessment
f MPO and/or other factors that may relate to plaque
ulnerability may help to better identify groups of
atients at high risk of CVD events.
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